Jerel Davis's Form 4/A amendment
AmendedChinook Therapeutics, Inc. (KDNY) · filed Mar 3, 2022
- Accession no.
- 0000899243-22-009071
- Filed
- Mar 3, 2022
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jan 5, 2022
This filing lists no transactions. It carries over 3 transactions from the original filing that it did not restate. Open-market sales total $16.0M.
This amendment restates part of 0000899243-22-000937 (filed Jan 5, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jerel DavisCIK 0001745958 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000899243-22-000937 (filed Jan 5, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2022 | Common Stock | SSaleDisposed | −600,000 | $16.00F2 | −$9,600,000 | 3,623,023 | Indirect | |
| Jan 3, 2022 | Common Stock | SSaleDisposed | −308,000 | $16.00F2 | −$4,928,000 | 1,863,197 | Indirect | |
| Jan 3, 2022 | Common Stock | SSaleDisposed | −92,000 | $16.00F2 | −$1,472,000 | 552,149 | Indirect |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Referenced by the price of 3 transactions in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
This amendment has no footnotes.
Remarks
This amended Form 4 is being filed to correct an inadvertent omission from the Reporting Person's Form 4s filed on August 27, 2021 and January 5, 2022 (the "Prior Form 4s"), which omitted the securities held directly by the Reporting Person. This Form 4 amendment amends the Prior Form 4s by including the Reporting Person's direct holdings.